FY2025 · ended Dec 31, 2025 · Revenue $72.59M, +105.8% YoY · Filed Mar 17, 2026
Bicycle Therapeutics plc (BCYC) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $72.6 million and a net loss of $219.0 million. Free cash flow was -$252.0 million. As of Sep 30, 2026 it held $469.9 million in cash and investments and $14.7 million in total debt.
Revenue (TTM)
$83.53M
+194.7% vs year-ago TTM
Net income (TTM)
$-141.79M
+43.4% vs year-ago TTM
Operating cash flow (TTM)
$-175.18M
+26.9% vs year-ago TTM
Free cash flow (TTM)
$-177.04M
+26.8% vs year-ago TTM
EPS (TTM)
$-2.03
+43.9% vs year-ago TTM
Dividend per share (TTM)
$0.00
Shares outstanding
69.37M
+0.4% vs prior year
Net cash
$455.25M
as of Sep 30, 2026
Operating margin
-189.4%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BCYC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Cambridge, United Kingdom
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1761612
- Former names
- BICYCLE THERAPEUTICS Ltd (until May 24, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $72.6M | $35.3M | $27.0M | $14.5M | $11.7M |
| Operating income | -$247.1M | -$209.9M | -$189.9M | -$116.7M | -$65.6M |
| Net income | -$219.0M | -$169.0M | -$180.7M | -$112.7M | -$66.8M |
| Diluted EPS | -$3.16 | -$2.90 | -$5.08 | -$3.80 | -$2.67 |
| Operating cash flow | -$249.7M | -$164.7M | -$60.6M | -$86.1M | -$14.8M |
| Free cash flow | -$252.0M | -$166.0M | -$63.6M | -$105.1M | -$16.8M |
| Total assets | $717.6M | $956.9M | $595.3M | $410.6M | $479.8M |
| Total liabilities | $107.6M | $163.8M | $224.4M | $139.8M | $133.5M |
| Stockholders' equity | $610.0M | $793.1M | $370.9M | $270.8M | $346.3M |
| Cash and investments | $628.1M | $879.5M | $526.4M | $339.2M | $438.7M |
| Total debt | $17.5M | $10.3M | $45.0M | $44.3M | $44.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 20, 2026 | Aug 18, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 17, 2026 |
All 660 Bicycle Therapeutics plc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.